Bristol Myers to sell psoriasis drug at over 80% discount

Core Insights - Bristol Myers Squibb will sell its psoriasis drug Sotyktu directly to cash-paying patients at a discount exceeding 80% from the drug's list price [1] Company Summary - The decision to offer Sotyktu at a significant discount indicates a strategic move by Bristol Myers Squibb to enhance accessibility for patients who pay out-of-pocket [1]